Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing (cervical screening) alone, suggests a study published on bmj.com.
[More]
A team of disease experts and health economists at Johns Hopkins warns that steadily declining rates of U.S. infant male circumcision could add more than $4.4 billion in avoidable health care costs if rates over the next decade drop to levels now seen in Europe.
[More]
Soon all adolescent boys may be vaccinated against the sexually transmitted disease that causes some forms of cancer under an extension of a scheme now available to girls, the Australian government's expert panel has recommended. The committee adds that the shots would also widen immunity to the virus, which would further reduce the risk to women and stem the spread of genital warts in both sexes.
[More]
Cervarix is currently offered to girls aged 12 and 13 years to protect against strains of the sexually transmitted human papillomavirus (HPV), which causes most cases of cancer of the cervix, the neck of the womb. Cervarix was picked by the Labour government for the first four-year phase of the NHS programme in 2008 because it offered ‘best overall value’ and more than five million doses have been given.
[More]
Graceway Pharmaceuticals announced today that the Food and Drug Administration has approved Zyclara Cream for the treatment of external genital and perianal warts in patients 12 years of age and older.
[More]
The Pharmaceutical Benefits Advisory Committee (PBAC) is deciding on whether to include the human papillomavirus (HPV) vaccine, Gardasil in in the National Immunization Program for boys.
[More]
Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).
[More]
New figures have shown an alarming rise in sexually transmitted infections among the over-50s in Britain. Health charity FPA (Flamily Planning Association) has come up with a nation wide campaign using fashion adverts from the 60s and 70s to encourage members of the baby boomer generation to use condoms and practice safe sex.
[More]
On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.
[More]
Summer is all about barbeques and lazy days at the pool. It's also a good time to start thinking about preparing for flu season, and the vaccinations you or your child may need for the upcoming year, says Carrie Maffeo, a professor of pharmacy at Butler University, who specializes in immunizations.
[More]
Helix BioPharma Corp. today announced financial results for the third quarter ended April 30, 2010.
[More]
China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approval for its SPR-based HPV-DNA chip from the State Food and Drug Administration of China (the "SFDA").
[More]
Helix BioPharma Corp. today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).
[More]
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
[More]
A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.
[More]
Men infected with human papillomavirus are at greater risk of becoming infected with human immunodeficiency virus than men who are not HPV positive, according to researchers at the University of North Carolina at Chapel Hill.
[More]
Nearly all U.S. states offer the human papillomavirus vaccine to adolescent girls who have been arrested or detained, according to a new report from The Miriam Hospital and Brown University. The study, published in the May issue of the Journal of Adolescent Health, offers the first nationwide review of HPV vaccination practices among juvenile justice facilities.
[More]
The tourist season may not be quite as healthy for the locals as it was before. In an eight year old study conducted by the Sydney Sexual Health Care Centre some scary facts have come to light. The study was based on about 5,700 backpackers who belonged mostly to the UK or Ireland and were in their mid twenties.
[More]
A small new study suggests that some common beliefs about the spread of sexually transmitted diseases may not apply to human papillomavirus, also known as HPV.
[More]
Helix BioPharma Corp. announced today that it has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts.
[More]